期刊文献+

Effects of Yishenbupi (Tonifying-Kidney and Invigorating-Spleen) prescription on renal fibrosis

下载PDF
导出
摘要 Background:This study aims to observe the effects of Yishenbupi(Tonifying-Kidney and Invigorating-Spleen)decoction on renal fibrosis of unilateral ureteral occlusion rats.Methods:Forty-eight sprague-dawley rats were randomly divided into the sham-operated group(sham group),model group,irbesartan group,and Yishenbupi group.Each group was intragastrically administered after the unilateral ureteral occlusion model was established.Rats in the Yishenbupi group were intragastrically administered with Yishenbupi decoction(18 g/kg/d)once every morning.Rats in the irbesartan group were intragastrically administered with 10 mg/kg/d of irbesartan tablets once every morning.Rats in the sham group and model group(unilateral ureteral occlusion group)were intragastrically administered with isovolumetric distilled water twice a day from the day the model was established.All rats were sacrificed 21 days later.Occluded kidney tissues were taken,and pathological sections were prepared.Masson,periodic acid-Schiff,Sirius Red,and immunohistochemical staining were performed to detect the expression of collagen III and fibronectin.Results:The pathological staining of rat kidneys(Masson,periodic acid-Schiff,and Sirius Red)showed that,compared to the unilateral ureteral occlusion model group,the renal interstitial injury was eased and collagen deposition was reduced in the irbesartan and Yishenbupi groups;after immunohistochemical staining,the expression of collagen III and fibronectin positively expressed cells was decreased and decreased more in the Yishenbupi group than in the irbesartan group.Conclusion:Yishenbupi decoction can alleviate the injury to kidney tissues in rats with unilateral ureteral obstruction,reduce the deposition of extracellular matrix,and act against renal fibrosis.
出处 《Drug Combination Therapy》 2020年第4期149-156,共8页 药物联合治疗
基金 This study was supported by National Natural Science Foundation of China(No.81460719) Guangxi Natural Science Foundation(No.2017GXNSFAA198217).
  • 相关文献

参考文献4

二级参考文献51

  • 1余学清,祝胜郎,娄宁,郑勋华,董秀清.依那普利对梗阻性肾病大鼠肾组织p38丝裂素激活蛋白激酶活性的影响[J].中华肾脏病杂志,2004,20(3):181-185. 被引量:2
  • 2李建军,陈香美,顾玥,魏日胞,师锁柱,尹忠.复方肾华片对5/6肾切除大鼠的疗效观察[J].中国中药杂志,2005,30(5):377-381. 被引量:6
  • 3刘震,周树录,谭建三,王峥,王增贵,张晓东,余运成.大鼠系膜增殖型肾小球肾炎模型的改进[J].华西医科大学学报,1996,27(2):182-184. 被引量:58
  • 4Pimentel JL,Sundell CL,Wang S,et al.Role of angiotensin Ⅱ in the expression and regulation of transforming growth factor-beta in obstrouctive nephropathy.Kidney Int,1995,48(4):1233-1246.
  • 5Ishidoya S,Morrissey J,McCracken R,et al.Angiotensin Ⅱ receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction.Kidney Int,1995,47(5):1285-1294.
  • 6Vaughan ED Jr,Marion D,Poppas DP,et al.Pathophysiology of unilateral ureteral obstruction:studies from charlottesville to new york.J Urol,2004,172(6 Pt 2):2563-2569.
  • 7Fan JM,Ng YY,Hill PA,et al.Transforming growth factor-β regulates tubular epithelial-myofibroblast transdifferentiation in vitro.Kidney Int,1999,56(4):1455-1467.
  • 8Moustakas A.Smad signaling network.J Cell Sci,2002,115(pt 17):3353-3356.
  • 9Poncelet AC,de-Caestecker MP,Schnaper HW.The transforming growth factor-beta/SMAD signaling pathway is present and functional in human mesangial cells.Kidney Int,1999,56(4):1354-1365.
  • 10Li JH,Zhu HJ,Huang XR,et al.Smad7 inhibits fibrotic effect of TGF-Beta on renal tubular epithelial cells by blocking Smad2 activation.J Am Soc Nephrol,2002,13(6):1464-1472.

共引文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部